Coopersurgical Patent-Cliff Exposure & CMS Drug Spending Portfolio

Coopersurgical (US): 4 reconciled FDA prescription therapies (1.1% 2025 to 2030 cliff risk), $45.7M 2024 CMS Part D & Medicaid spend, and $1,085 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure1.1%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$45.7M
2024 Medicare Part D Spend$372
2024 Medicaid Spend$45.7M
California HCAI SB 17 FilingsSpecialty launch notice ($1,085 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CooperCompanies across sibling Meru public-data platforms.